Hokuriku Pharmaceutical announced that it recently received the “Drug Registration Certificate” for pioglitazone metformin tablets approved and issued by the State Drug Administration. This drug is suitable for type 2 diabetics currently treated with pioglitazone hydrochloride and metformin hydrochloride in combination or type 2 diabetics with poor blood sugar control after treatment with metformin hydrochloride alone on the basis of diet control and exercise. According to data from the Mi Intranet, in 2024, sales of pioglitazone metformin tablets in China's three major terminals and six major markets were about 1,674 billion yuan, of which the sales of urban public hospitals and county-level public hospitals were 1,183 million yuan, the sales of urban community centers and township health hospitals were 195 million yuan, and the sales volume of urban physical pharmacies and online pharmacies was 296 million yuan.

Hokuriku Pharmaceutical announced that it recently received the “Drug Registration Certificate” for pioglitazone metformin tablets approved and issued by the State Drug Administration. This drug is suitable for type 2 diabetics currently treated with pioglitazone hydrochloride and metformin hydrochloride in combination or type 2 diabetics with poor blood sugar control after treatment with metformin hydrochloride alone on the basis of diet control and exercise. According to data from the Mi Intranet, in 2024, sales of pioglitazone metformin tablets in China's three major terminals and six major markets were about 1,674 billion yuan, of which the sales of urban public hospitals and county-level public hospitals were 1,183 million yuan, the sales of urban community centers and township health hospitals were 195 million yuan, and the sales volume of urban physical pharmacies and online pharmacies was 296 million yuan.